ArticleFrontiers in immunology2026
CNNeoPP: a large language model-enhanced deep learning pipeline for personalized neoantigen prediction and liquid biopsy applications.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- From Neoantigens to Nanocarriers: Modern Methods and Modalities in Using Peptides for Cancer Vaccination.Biochemistry · 2026Review
- Causal AI for cancer immunotherapy: a narrative framework review of target trial emulation, treatment-effect learning and clinical translation.Frontiers in immunology · 2026Review
- Personalised neoantigen vaccines for precision oncology in Southeast Asia: clinical opportunities, infrastructure challenges, and policy perspectives.Frontiers in immunology · 2026Review
- mRNA processing in cancer immunotherapy: emerging targets, resistance mechanisms, and therapeutic opportunities.Frontiers in immunology · 2026Review
- Computational identification of B- and T-cell epitopes: a unified task taxonomy and review of databases, datasets, predictive pipelines, and gaps.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoantigens have emerged as promising targets for personalized cancer immunotherapy. However, accurate identification of immunogenic neoantigens remains a challenge due to limitations in existing predictive models. Here, we present CNNeo, a novel deep learning-based neoantigen prediction model, and CNNeoPP, an integrated computational pipeline for neoantigen discovery. CNNeo employs large language model-derived sequence representations and multi-modal feature integration, demonstrating superior predictive performance compared to existing tools. CNNeoPP was rigorously validated using independent datasets, including the TESLA dataset, and experimental validation via ELISpot T-cell assays. Additionally, we conducted a proof-of-concept study utilizing plasma cell-free DNA to explore the feasibility of non-invasive neoantigen prediction. We found that increased sequencing depth enhances neoantigen detectability, further amplified by the prioritization strategy of CNNeoPP. CNNeoDB, a publicly accessible database was developed compiling neoantigen data from multiple sources. This study establishes robust tools for neoantigen prediction, with implications for optimizing cancer immunotherapy and liquid biopsy-based tumor monitoring. CNNeoPP is available at https://github.com/AaronChen007/neoantigen.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.